Literature DB >> 20709376

Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy.

Deborah A Ahove1, Karen E Hoffman, Jim C Hu, Toni K Choueiri, Anthony V D'Amico, Paul L Nguyen.   

Abstract

OBJECTIVES: To determine the predictors of late prostate-specific antigen (PSA) failure among men with an undetectable PSA level 5 years after radical prostatectomy (RP).
METHODS: A total of 505 men who had undergone RP for prostate cancer from 1985 to 2000 at Brigham and Women's Hospital and who had ≥ 5 years of recurrence-free survival (ie, all PSA levels < 0.2 ng/mL) constituted the study cohort. Cox multivariate regression analysis was used to determine the factors associated with PSA failure after 5 years. Kaplan-Meier analysis was used to estimate the PSA failure-free survival rate.
RESULTS: The median follow-up was 10.7 years after RP (interquartile range 7.8-13.3). No patient had PSA failure at year 5, but the PSA failure-free survival rate for this cohort at year 10 was 88% (95% confidence interval 84.4%-91.0%) and, at year 13, was 82% (95% confidence interval 77.0%-86.0%). On multivariable regression analysis, the factors associated with failure after year 5 were Gleason score 7 (adjusted hazard ratio [AHR] 1.88, P = .036), Gleason score 8-10 (AHR 4.81, P ≤ .002), extracapsular extension (AHR 2.37, P = .003), and seminal vesicle invasion (AHR 1.52, P = .062).
CONCLUSIONS: Among men with an undetectable PSA level 5 years after RP, Gleason score 7, Gleason score 8-10, extracapsular extension, and seminal vesicle invasion were significant predictors of subsequent late PSA failure. Patients with these factors (particularly Gleason score 8-10 or seminal vesicle invasion) should have continued close monitoring of their PSA level and consideration of early salvage, as appropriate. However, patients with Gleason score 6 disease were very unlikely to develop late recurrence and might be candidates for less-intense follow-up once they have passed the 5-year mark.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709376     DOI: 10.1016/j.urology.2010.03.092

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  13 in total

1.  Prostate cancer: Postoperative PSA surveillance in patients treated with radical prostatectomy: might less be more?

Authors:  Nick Warde
Journal:  Nat Rev Urol       Date:  2010-10       Impact factor: 14.432

2.  Can we stop prostate specific antigen testing 10 years after radical prostatectomy?

Authors:  Stacy Loeb; Zhaoyong Feng; Ashley Ross; Bruce J Trock; Elizabeth B Humphreys; Patrick C Walsh
Journal:  J Urol       Date:  2011-06-15       Impact factor: 7.450

Review 3.  The biology and clinical implications of prostate cancer dormancy and metastasis.

Authors:  Colm Morrissey; Robert L Vessella; Paul H Lange; Hung-Ming Lam
Journal:  J Mol Med (Berl)       Date:  2015-10-21       Impact factor: 4.599

Review 4.  The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow.

Authors:  Hung-Ming Lam; Robert L Vessella; Colm Morrissey
Journal:  Drug Discov Today Technol       Date:  2014-03

5.  Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway.

Authors:  Li-Yuan Yu-Lee; Guoyu Yu; Yu-Chen Lee; Song-Chang Lin; Jing Pan; Tianhong Pan; Kai-Jie Yu; Bin Liu; Chad J Creighton; Jaime Rodriguez-Canales; Pamela A Villalobos; Ignacio I Wistuba; Eulalia de Nadal; Francesc Posas; Gary E Gallick; Sue-Hwa Lin
Journal:  Cancer Res       Date:  2018-03-07       Impact factor: 12.701

6.  Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer.

Authors:  D M Bolton; A Ta; M Bagnato; D Muller; N L Lawrentschuk; G Severi; R R Syme; G G Giles
Journal:  World J Urol       Date:  2013-07-04       Impact factor: 4.226

7.  Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era.

Authors:  Ahva Shahabi; Raj Satkunasivam; Inderbir S Gill; Gary Lieskovsky; Sia Daneshmand; Jacek K Pinski; Mariana C Stern
Journal:  Can Urol Assoc J       Date:  2016-01-14       Impact factor: 1.862

Review 8.  Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity.

Authors:  Johnny Kao; Jamie A Cesaretti; Nelson N Stone; Richard G Stock
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

Review 9.  Dormancy in solid tumors: implications for prostate cancer.

Authors:  Nazanin S Ruppender; Colm Morrissey; Paul H Lange; Robert L Vessella
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

Review 10.  Therapeutic options in patients with biochemical recurrence after radical prostatectomy.

Authors:  Ovidiu Gabriel Bratu; Camelia Cristina Diaconu; Dan Liviu Dorel Mischianu; Traian Constantin; Ana Maria Alexandra Stanescu; Simona Gabriela Bungau; Florentina Ionita-Radu; Radu Dragos Marcu
Journal:  Exp Ther Med       Date:  2019-08-20       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.